1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

JAK and PI3K Signaling Pathway Markets

  • April 2014
  • 143 pages
  • BCC Research
Report ID: 2114687


Table of Contents


The global market for signal transduction therapies/inhibitors (JAK and PI3K) reached $173.5 million in 2012. This market is expected to grow to $464.5 million in 2013 and $2.2 billion in 2018 with a compound annual growth rate (CAGR) of 36.8% over the five-year period from 2013 to 2018.

This report provides:

An overview of the global market for signal transduction therapies and inhibitors
Analyses of global market trends, with data from 2012, estimates for 2013, and projections of CAGRs through 2018
Information on approved products such as Ruxolitnib, as well as others in devlopment
Discussion of the regulatory environment which is impacting development
Relevant patent analysis
Profiles of leading companies in the industry


The intent of the report carried out by BCC Research was to assess, explore and envisage the market potential of signal transduction therapies and to review the advancement of the several candidates in their clinical developments for therapies concerning the aberrant signals through janus kinase (JAK) and phosphoinositide 3-kinases (PI3K) pathways. The emerging market analysis for the therapies associated with JAK and PI3K deviant cellular signals is brought together from the approved product performance, the notable clinical developments, the judicious collaborations for advancement of successful research, commercialization plans, huge market opportunities, etc.

The report establishes a balanced projection on the budding market of JAK and PI3K based signal transduction therapies with just two products ruxolitinib (Jakafi) and tofacitinib (Xaljanz). Ruxolitinib was approved in November 2011 for myelofibrosis while tofacitinib was approved in November 2012 for rheumatoid arthritis, respectively. The report also projects the future market for the said therapies, candidate details and their clinical development status, biomarker research, market leaders and market shares, profile of leading companies, collaboration and commercialization strategies, technology platforms and new developments, regulatory aspects, patent details, opportunities and challenges, and drivers and factors determining the signal transduction therapies market for JAK and PI3K.

The sales data for ruxolitinib and tofacitinib is secured from the germane sources that comprise the annual reports of the manufacturing companies and other data sources. Market analysis is conducted for the periods from 2011 until 2013. The report also presents the revenue forecast for the year 2018 with a drilled down analysis on the region wise data for North America (U.S. and Canada), Europe and emerging markets for the examined period.


Significant developments have come about in both the understanding of the complexity of signal transduction pathways such as JAK and PI3K over the past couple of years. At the same time, much progress occurred in the isolation of target specific therapies/inhibitors for the abnormal signals in those pathways. The therapies for JAK and PI3K cellular signal pathways predominantly focus on the cancer lines and inflammatory diseases after the approval of ruxolitinib (for myelofibrosis) and tofacitinib (for rheumatoid arthritis). Although other diseases categories like asthma, skin, respiratory and eye disorders are also being explored largely. The report portrays the prospective therapeutic application of the JAK and PI3K inhibitors/therapies/biomarkers from the perspective of their market opportunity, disease targets, clinical development progress, etc.

The growing market of therapies related to JAK and PI3K signal pathways have tremendous opportunity to grow since these therapies have the potential to target diseases like cancer and inflammatory diseases with no appropriate medications so far. The current therapies are capable of reducing the disease burden but cannot cure. Furthermore, there is a growing patient base worldwide for cancers and inflammatory diseases.


The report emphasizes on the prospective remedial relevance of the signal transduction therapies for JAK and PI3K signaling pathways as well as the market demand of those therapies. The major developments in this category of medical science would be useful for the product developers/manufacturers/producers, multinationals, scientists, researchers, research universities, government and non-government organizations, and others.


BCC Research conducted the market evaluation, the global and regional breakdown of sales data, present and prospective application of the therapies, market forecasting, success and challenges, patent details, regulatory facet, clinical developments, market leaders and market share of the maturing market for JAK and PI3K inhibitors/therapies/biomarkers.
The sales data for the global and regional markets is validated for the present and projected values through scientific and statistical analysis. The information regarding the approved products and candidates as well as the technologies/platforms are provided based on their present/prospective application and viability.


BCC Research composed all relevant information for the report on signal thransduction therapies/inhibitors/biomarkers for JAK and PI3K signaling pathways through primary as well as secondary research methodologies. BCC Research interviewed industry practice leaders that included developers/producers of JAK and PI3K therapies, domain experts, scientists and other veterans from the industry. Furthermore, BCC Research conducted searches through several information sources. Market predictions depict the probable unit prices, usage of JAK and PI3K inhibitors/therapies/biomarkers, present-day economy and conceivable application of JAK and PI3K inhibitors/therapies/biomarkers.


BCC Research explored appropriate organizations and companies to accrue relevant data associated with JAK and PI3K inhibitors/therapies/biomarkers. The organizations were key producers and research organizations/universities of JAK and/or PI3K therapies. BCC Research also met with representatives of the companies and research groups to achieve deeper insights on the future perspectives of signal transduction therapies for JAK and PI3K signaling pathways.
BCC Research reviewed scientific journals, booklets, research papers and articles, company white papers, pharmaceutical and other relevant newsletters, science digests, online medical libraries, medical and pharmaceutical blogs, news feeds, medical papers and journals, newsletters, company literature and financial reports, product literature, periodicals, abstracts, regulatory aspects, technical articles, bulletins, patent files, pharmaceutical biopharmaceutical and medicine databases, etc.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Amrita helps you find the right report:


The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Axial spondyloarthritis (axSpA) Market and Forecast Analyst to 2024

  • $ 22000
  • Industry report
  • April 2017
  • by Datamonitor Healthcare

Introduction Axial spondyloarthritis (axSpA) is a chronic, systemic, inflammatory rheumatic disease that predominantly affects the spine and sacroiliac (SI) joints, leading to chronic back pain. The chronic ...

OpportunityAnalyzer: Ovarian Cancer - Opportunity Analysis and Forecasts to 2025

  • $ 10995
  • Industry report
  • May 2017
  • by GlobalData

OpportunityAnalyzer: Ovarian Cancer - Opportunity Analysis and Forecasts to 2025 Summary Ovarian cancer is the fifth most common malignancy in women and is the leading cause of death among gynecological ...

PharmaPoint: Chronic Obstructive Pulmonary Disease - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • May 2017
  • by GlobalData

PharmaPoint: Chronic Obstructive Pulmonary Disease - Global Drug Forecast and Market Analysis to 2025 Summary COPD is a progressive lung disease characterized by an abnormal inflammatory response and airflow ...

Nash: Kol Insight [2017]

June 2017 $ 9015

Car-t Disease Outlook [2017]

June 2017 $ 8355

Download Unlimited Documents from Trusted Public Sources

Anti-Infective and Therapy Market in Brazil

  • August 2017
    11 pages
  • Anti-Infective  



View report >

Anti-Infective Market in the US

  • August 2017
    9 pages
  • Anti-Infective  

  • United States  

View report >

Anti-Infective Market in the UK

  • August 2017
    21 pages
  • Anti-Infective  

    Antibiotic Resi...  

  • United Kingdom  


View report >

Diabetes Statistics

10 days ago

Related Market Segments :



Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.